

Final Appraisal Recommendation

Advice No: 2218 – December 2018

Dolutegravir/rilpivirine (Juluca®) 50 mg/25 mg film-coated tablet

Submission by ViiV Healthcare Ltd

Recommendation of AWMSG

Dolutegravir/rilpivirine (Juluca®) is recommended as an option for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- dolutegravir/rilpivirine (Juluca®) should be used in line with All Wales Guidance for HIV treatment.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2850), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2218:
Dolutegravir/rilpivirine (Juluca®) 50 mg/25 mg film-coated tablet December 2018